Skip to main content
Equibles

UBS Group AG

Position in BMY — Bristol Myers Squibb Co

CIK 1610520 ZURICH, V8
Back to BMY Full portfolio

Position in BMY

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$436,707,230
+$104,916,251 QoQ
Shares Held
7,200,449
+17.1% QoQ
Ownership
0.353%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 55.9246235894456.ToString("F0")% Shared 0.ToString("F0")% None 44.0753764105544.ToString("F0")%

Common Shares in BMY Over Time

Shares Held

Position Value (USD)

Derivatives in BMY

reported options exposure · as of Mar 31, 2026
CallValue
$18,395,145
CallShares
303,300
PutValue
$13,100,400
PutShares
216,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

UBS Group AG holds $15,459,459,109 across 21 Drug Manufacturers - General names. BMY ranks #9 (2.8% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 4,043,568 $3,719,152,536
2 ABBV
AbbVie Inc.
 14,051,196 $3,055,994,614
3 JNJ
Johnson & Johnson
 10,209,327 $2,495,567,886
4 MRK
Merck & Co., Inc.
 13,933,630 $1,676,076,347
5 AZN
Astrazeneca PLC
 5,981,411 $1,179,653,872
6 AMGN
Amgen Inc
 3,148,040 $1,107,637,870
7 GILD
Gilead Sciences, Inc.
 3,930,216 $547,754,202
8 PFE
Pfizer Inc
 17,609,150 $494,464,929

All Filings in BMY

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $13,100,400 216,000
2026-03-31 $436,707,230 7,200,449
2026-03-31 $18,395,145 303,300
2025-12-31 $90,651,186 1,680,593
2025-12-31 $331,790,979 6,151,112
2025-12-31 $47,488,776 880,400
2025-09-30 $10,950,505 242,805
2025-09-30 $65,913,334 1,461,493
2025-09-30 $480,619,784 10,656,758
2025-06-30 $8,404,180 181,555
2025-06-30 $573,333,540 12,385,689
2025-06-30 $25,325,259 547,100
2025-03-31 $20,315,769 333,100
2025-03-31 $587,481,353 9,632,421
2025-03-31 $32,734,979 536,727
2024-12-31 $37,529,087 663,527
2024-12-31 $71,695,456 1,267,600
2024-12-31 $543,779,602 9,614,208
2024-09-30 $34,011,133 657,347
2024-09-30 $48,526,946 937,900
2024-09-30 $394,852,098 7,631,467
2024-06-30 $272,160,995 6,553,359
2024-06-30 $6,081,113 146,427
2024-06-30 $26,670,566 642,200
2024-03-31 $16,346,386 301,427
2024-03-31 $413,071,698 7,617,033
2024-03-31 $29,132,356 537,200
2023-12-31 $249,973,391 4,871,826
2023-12-31 $90,977,761 1,773,100
2023-12-31 $107,032,660 2,086,000
2023-09-30 $92,742,116 1,597,900
2023-09-30 $110,287,608 1,900,200
2023-09-30 $401,639,990 6,920,055
2023-06-30 $393,696,598 6,156,319
2023-06-30 $66,597,530 1,041,400
2023-06-30 $106,291,295 1,662,100
2023-03-31 $127,301,677 1,836,700
2023-03-31 $86,893,947 1,253,700
2023-03-31 $414,853,478 5,985,478
2022-12-31 $491,001,979 6,824,211
2022-12-31 $200,157,705 2,781,900
2022-12-31 $91,304,550 1,269,000
2022-09-30 $38,921,775 547,500
2022-09-30 $130,727,401 1,838,900
2022-09-30 $388,467,038 5,464,440
2022-06-30 $128,366,700 1,667,100
2022-06-30 $453,753,608 5,892,904
2022-06-30 $37,984,100 493,300
2022-03-31 $119,739,988 1,639,600
2022-03-31 $467,483,504 6,401,253

Report a Problem

Category
Description
Email (optional, for follow-up)